ClinicalTrials.gg
RecruitingNCT07652775Updated Jun 17, 2026

rTMS Combined With Aerobic Exercise for Older Adults With Mild Cognitive Impairment and Comorbid Depression

An interventional study of Repetitive Transcranial Magnetic Stimulation and Aerobic Exercise in Mild Cognitive Impairment (MCI) and Depressive Symptoms, sponsored by Cheng-Hsin General Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Cheng-Hsin General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2026, registered Jun 2026).
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Cognitive Dysfunction with a site in Taiwan — 24 open to participants now, 29 under way, 3 of them phase 3. Cognitive Dysfunction · Taiwan.

Planned enrollment
66th of 94
45 · median 62
Started
2026
with 4 others
No phase
78 of 111
15 open now
Primary completion
2027-12
later than 18 of 28 live
Registered
109th of 111
by date

Among the 111 studies in Cognitive Dysfunction with a site in Taiwan, this one is the 66th largest by planned enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2026, is one of 78 with no phase, reaches primary completion later than 18 of the 28 other live ones, and was the 109th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

24 of the 111 studies in Cognitive Dysfunction with a site in Taiwan are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Cognitive Dysfunction with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) and aerobic exercise on cognitive function and mental health in older adults with mild cognitive impairment (MCI) and comorbid depression. Forty-five participants will be randomly assigned to one of three groups: (1) rTMS alone, (2) rTMS combined with stationary cycling exercise, or (3) sham rTMS combined with stationary cycling exercise. Participants will receive 20 intervention sessions over a 5-week period (4 sessions per week). Outcomes, including cognitive function, depressive symptoms, sleep quality, life satisfaction, self-efficacy, and gait performance, will be assessed at baseline, immediately after completion of the 5-week intervention, and at a 1-month follow-up. The findings may contribute to the development of evidence-based, non-pharmacological interventions for improving cognitive and mental health outcomes in older adults with MCI and comorbid depression.

Read the detailed description

Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia and is frequently accompanied by depressive symptoms. Older adults with MCI and comorbid depression are at increased risk of cognitive decline, functional impairment, reduced quality of life, and progression to dementia. Therefore, effective non-pharmacological interventions targeting both cognitive and mental health outcomes are needed.

This study aims to investigate the effects of rTMS alone and rTMS combined with aerobic exercise on cognitive and mental health outcomes in older adults with MCI and comorbid depression. A randomized controlled trial design will be employed. Forty-five eligible participants who provide written informed consent will be randomly assigned to one of three groups: (1) rTMS alone, (2) rTMS combined with stationary cycling exercise, and (3) sham rTMS combined with stationary cycling exercise.

All participants will receive 20 intervention sessions over a 5-week intervention period (4 sessions per week). Intervention sessions will be conducted on Monday, Tuesday, Thursday, and Friday. Participants in the rTMS-alone group will receive a 5-minute rTMS session only. Participants in the rTMS combined with stationary cycling exercise group and the sham rTMS combined with stationary cycling exercise group will receive either active or sham rTMS for 5 minutes, followed by 30 minutes of stationary cycling exercise.

The stimulation target will be the left dorsolateral prefrontal cortex (DLPFC). For sham stimulation, a figure-of-eight coil will be positioned with one wing angled at 90 degrees relative to the scalp and maintained approximately 3 cm from the scalp surface to mimic the sensory experience of active stimulation while minimizing effective cortical stimulation.

Outcome assessments will be conducted at baseline, immediately after completion of the 5-week intervention period, and at a 1-month follow-up. Outcome measures will include cognitive function, depressive symptoms, sleep quality, life satisfaction, self-efficacy, and gait performance. Each assessment session is expected to require approximately 45 minutes.

The findings may provide evidence supporting the application of combined neuromodulation and aerobic exercise interventions for improving cognitive and mental health outcomes in older adults with MCI and comorbid depression.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Depressive Symptoms

Keywords

  • Repetitive Transcranial Magnetic Stimulation
  • Aerobic Exercise
  • Dual-Task Walking
  • Timed Up and Go
  • Cognitive Function
  • Older Adults
  • Life Satisfaction
  • Gait Performance
  • rTMS
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 65 to 90 years.
  2. Diagnosed with mild cognitive impairment (MCI) according to established clinical criteria.
  3. Presence of depressive symptoms as determined by clinical assessment and Beck Depression Inventory-II (BDI-II).
  4. Able to communicate and follow study instructions.
  5. Able to ambulate independently with or without an assistive device.
  6. Able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of dementia.
  2. History of epilepsy or seizure disorder.
  3. Presence of metallic implants, pacemakers, cochlear implants, or other to transcranial magnetic stimulation.
  4. Major neurological disorders, including stroke, Parkinson's disease, traumatic brain injury, or other neurodegenerative diseases.
  5. Severe psychiatric disorders other than depression.
  6. Severe cardiovascular, musculoskeletal, or medical conditions that preclude participation in aerobic exercise.
  7. Severe visual or hearing impairments that interfere with cognitive assessment.
  8. Current participation in another intervention study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    rTMS Alone

    Participants receive active repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex (DLPFC). Stimulation sessions are conducted 4 times per week for 5 weeks (20 sessions total).

    Device: Repetitive Transcranial Magnetic Stimulation

  • Experimental
    rTMS Combined With Aerobic Exercise

    Participants receive active repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex (DLPFC), immediately followed by 30 minutes of moderate-intensity stationary cycling exercise. Sessions are conducted 4 times per week for 5 weeks (20 sessions total).

    Device: Repetitive Transcranial Magnetic Stimulation · Behavioral: Aerobic Exercise

  • Experimental
    Sham rTMS Combined With Aerobic Exercise

    Participants receive sham repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex (DLPFC), immediately followed by 30 minutes of moderate-intensity stationary cycling exercise. Sham stimulation is delivered using a figure-of-eight coil positioned at a 90-degree angle relative to the scalp and approximately 3 cm from the scalp surface to mimic the sensory and auditory experience of active stimulation without inducing effective cortical activation. Sessions are conducted 4 times per week for 5 weeks (20 sessions total).

    Behavioral: Aerobic Exercise · Device: Sham Repetitive Transcranial Magnetic Stimulation

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation

    Active repetitive transcranial magnetic stimulation (rTMS) is delivered over the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-eight coil. Participants receive stimulation sessions 4 times per week for 5 weeks (20 sessions total).

    Also known as: rTMS

  • BehavioralAerobic Exercise

    Participants perform 30 minutes of moderate-intensity stationary cycling exercise immediately following rTMS or sham rTMS sessions. Exercise sessions are conducted 4 times per week for 5 weeks (20 sessions total).

  • DeviceSham Repetitive Transcranial Magnetic Stimulation

    Sham stimulation is delivered using a figure-of-eight coil positioned at a 90-degree angle relative to the scalp and approximately 3 cm away from the scalp surface to mimic the sensory and auditory experience of active stimulation without producing effective cortical activation. Participants receive sham stimulation sessions 4 times per week for 5 weeks (20 sessions total).

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MoCA)

    Changes in global cognitive function measured using the Montreal Cognitive Assessment (MoCA). Higher scores indicate better cognitive performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

Secondary outcomes

  1. Geriatric Depression Scale-15 (GDS-15)

    Changes in depressive symptoms measured using the Geriatric Depression Scale-15 (GDS-15). Higher scores indicate greater depressive symptom severity.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  2. Pittsburgh Sleep Quality Index (PSQI)

    Changes in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI). Lower scores indicate better sleep quality.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  3. Trail Making Test Part A (TMT-A)

    Changes in attention and processing speed measured using the Trail Making Test Part A. Shorter completion times indicate better performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  4. Trail Making Test Part B (TMT-B)

    Shorter completion times indicate better executive functioning and cognitive flexibility.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  5. California Verbal Learning Test-Short Form (CVLT-SF)

    Changes in verbal learning and memory measured using the California Verbal Learning Test-Short Form (CVLT-SF). Higher scores indicate better verbal learning and memory performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  6. Stroop Color-Word Test

    Changes in executive function, selective attention, and inhibitory control measured using the Stroop Color-Word Test (SCWT). Performance is assessed as the number of correct responses completed within 1 minute. Higher scores indicate better executive function, selective attention, and inhibitory control.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  7. Digit Span Forward Test

    Changes in attention span and immediate verbal memory measured using the Digit Span Forward Test. Higher scores indicate better attention and short-term memory performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  8. Digit Span Backward Test

    Changes in working memory and executive function measured using the Digit Span Backward Test. Higher scores indicate better working memory performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  9. Beck Depression Inventory-II (BDI-II)

    Higher scores indicate greater depressive symptom severity.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  10. EuroQol Five-Dimension Five-Level Questionnaire Index Score (EQ-5D-5L Index)

    Changes in health-related quality of life measured using the EuroQol Five-Dimension Five-Level Questionnaire Index Score (EQ-5D-5L Index). Higher scores indicate better health-related quality of life.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  11. World Health Organization Quality of Life-BREF (WHOQOL-BREF)

    Changes in quality of life measured using the World Health Organization Quality of Life-BREF (WHOQOL-BREF). Higher scores indicate better quality of life.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  12. Chinese Aging Well Profile (CAWP)

    Changes in subjective well-being measured using the Chinese Aging Well Profile (CAWP). Higher scores indicate better subjective well-being.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  13. Timed Up and Go Test (TUG)

    Changes in functional mobility measured using the Timed Up and Go Test (TUG). Participants are instructed to stand up from a chair, walk 3 meters, turn around, walk back, and sit down. Shorter completion times indicate better functional mobility and balance performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  14. EuroQol Visual Analogue Scale Score (EQ-VAS)

    Changes in self-rated health status measured using the EuroQol Visual Analogue Scale (EQ-VAS). Higher scores indicate better perceived health status.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  15. Dual-task gait speed (m/s)

    Changes in dual-task gait speed measured in meters per second (m/s). Higher values indicate better gait performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  16. Dual-task cadence (steps/min)

    Changes in dual-task cadence measured in steps per minute. Higher values indicate better gait performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  17. Dual-task stride length (m)

    Changes in dual-task stride length measured in meters. Higher values indicate better gait performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  18. Dual-task cost (%)

    Percentage change in gait performance during dual-task walking relative to single-task walking.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  19. Single-task gait speed (m/s)

    Walking speed during single-task walking, measured in meters per second.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  20. Single-task cadence (steps/min)

    Higher values indicate better gait performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

  21. Single-task stride length (m)

    Higher values indicate better gait performance.

    Time frame: Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 21 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2026
First posted
Jun 17, 2026
StartActual
Mar 3, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07652775
Lead sponsor
Cheng-Hsin General Hospital
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Mar 3, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Ya-Chu Chan, MS Candidate
Contact
aya45285@gmail.com
+886-983-559-807
Kai-Chen Wang, MD
principal investigator · Cheng-Hsin General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion